What is your preferred chemotherapy backbone (FOLFOX or FOLFIRI) when combining with encorafenib + cetuximab in the 1L setting for BRAF V600E-mutant mCRC?

In my practice, the treatment backbone regimen decision is driven by patient factors - thoughts about hair loss, current bowel function, performance status, existing neuropathy, and other comorbid conditions.

All things equal, I prefer FOLFOX. Recent updates from ASCO GI show good activity for FOLFI...

In general, metastatic colorectal cancer (non-BRAF V600E), FOLFOX, and FOLFIRI have demonstrated similar overall survival (approximately 30-31 months when combined with bevacizumab). The choice between them typically depends on:

• Toxicity profiles (Oxaliplatin causes more sensory neuropathy, while ir...